Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95184 | 0.91 | — | — | |
| SCHEMBL20602546 | 0.91 | — | — | |
| SCHEMBL20601919 | 0.91 | — | — | |
| SCHEMBL5408434 | 0.89 | HTR6 (0.32) | — | |
| SCHEMBL338531 | 0.84 | HTR6 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL368444 | 0.83 | HTR6 (0.39) | — | |
| SCHEMBL27491967 | 0.82 | HTR6 (0.33) | — | |
| SCHEMBL20742608 | 0.79 | — | — | |
| SCHEMBL8834900 | 0.64 | HTR6 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL4977845 | 0.64 | HTR6 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CDC7, CDK7, CDK17 | KDM4E 1628/4885ALDH1A1 2811/4885 |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | CDC7, CDK7, CDK17 | KDM4E 1583/4885ALDH1A1 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.